abstract |
The present invention relates to the fields of biotechnology and medicine, mono- and bi-sialylated sialic acid residues representing 40-60% of total glycans, and tri-sialylated sialic acid residues representing 40-43% of total glycans. , and microheterogeneity of fucosylated N-glycans formed by 2-, 3- and 4-antennary structures with tetrasialylated sialic acid residues representing 10-13% of total glycans. Pharmaceutical compositions of modified human erythropoietin are described. This glycosylation pattern confers properties on the compositions that allow their use in disorders of the nervous system. Methods of obtaining the pharmaceutical compositions described herein are also described. |